COVID-19 vaccine development: Setback for Sanofi and GSK candidate, University of Queensland and CSL abandon trial
Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.